Human Papillomavirus (HPV) is among the most common sexually transmitted infections in both females and males across the world that generally do not cause symptoms and are characterized by high rates of clearance. Persistent infections due at least to twelve well-recognized High-Risk (HR) or oncogenic genotypes, although less frequent, can occur, leading to diseases and malignancies, principally cervical cancer. Three vaccination strategies are currently available for preventing certain HR HPVs-associated diseases, infections due to HPV6 and HPV11 low-risk types, as well as for providing cross-protection against non-vaccine genotypes. Nevertheless, the limited vaccine coverage hampers reducing the burden of HPV-related diseases globally. For HR HPV types, especially HPV16 and HPV18, the E6 and E7 oncoproteins are needed for cancer development. As for other tumors, even in cervical cancer, non-coding microRNAs (miRNAs) are involved in posttranscriptional regulation, resulting in aberrant expression profiles. In this study, we provide a summary of the epidemiological background for HPV occurrence and available immunization programs. In addition, we present an overview of the most relevant evidence of miRNAs deregulation in cervic...Continue Reading
Proposals for the TNM classification and its extended application for malignant tumours of the head and neck regions
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines
Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.
Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6.
MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells
Prevalence and genotype identification of human papillomavirus in women undergoing voluntary cervical cancer screening in Molise, central Italy
Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus
Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls.
Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies
Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells
Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29.
Identification of miR-23a as a novel microRNA normalizer for relative quantification in human uterine cervical tissues.
Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein
miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1.
Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer
Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells
Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis
MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.
Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer
The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer.
MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells
Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta
MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells
Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy
MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor
Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population
Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme
Identification of miRNA-mRNA Regulatory Network and Construction of Prognostic Signature in Cervical Cancer
Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.